Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIMOHANDOPEN exploratory study of rimonabant for hand function in spinal cord injury
2025-524279-22-00Phase 2Authorised
- Sponsor
- Sinfatin
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rimonabant in spinal cord injury (SCI), sponsored by Sinfatin. Primary endpoint: Change in total GRASSP score. Planned start May 2026; status: authorised.
02
Drugs
rimonabant
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on 2025-524279-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524279-22-00.